• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

    68.95 -1.06 (-1.51%)
    Streaming Delayed Price Updated: 1:38 PM EDT, Aug 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 307,677
    Open 70.72
    Bid (Size) 68.69 (100)
    Ask (Size) 68.99 (300)
    Prev. Close 70.01
    Today's Range 68.49 - 71.34
    52wk Range 48.20 - 85.25
    Shares Outstanding 42,600,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Tarsus Pharmaceuticals Q2 Earnings Call Highlights ↗
    Tarsus Pharmaceuticals (NASDAQ:TARS) reported second-quarter growth in sales of its Demodex blepharitis treatment XDEMVY and announced a pending acquisition of Alkeus Pharmaceuticals, adding late-stage... 
    Via MarketBeat
    Topics Earnings
    News headline image
    Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire

    Performance

    YTD
    -14.6%
    -14.6%
    1 Month
    +16.3%
    +16.3%
    3 Month
    +6.6%
    +6.6%
    6 Month
    +5.4%
    +5.4%
    1 Year
    +34.2%
    +34.2%

    More News

    Read More
    News headline image
    Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Beats Q1 Estimates with Explosive XDEMVY Growth But Stock Slips ↗
    Via Chartmill
    TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Passes High-Growth Momentum and Minervini Trend Template Screen ↗
    Via Chartmill
    Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Q4 2025 Earnings: Revenue Soars on XDEMVY Sales, But Losses Widen ↗
    Via Chartmill
    News headline image
    Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline ↗
    Via MarketBeat
    News headline image
    Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme ↗
    Via Benzinga
    Topics Law Enforcement
    News headline image
    Tarsus to Participate in Upcoming Investor Conferences
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Tarsus to Participate in Upcoming Investor Conferences
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Tarsus (TARS) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire
    News headline image
    Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗
    Via The Motley Fool
    News headline image
    Tarsus to Participate in Upcoming Investor Conferences
    From Tarsus Pharmaceuticals, Inc
    Via GlobeNewswire

    Frequently Asked Questions

    Is Tarsus Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, Tarsus Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does Tarsus Pharmaceuticals, Inc. - Common Stock trade on?
    Tarsus Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for Tarsus Pharmaceuticals, Inc. - Common Stock is TARS on the Nasdaq Stock Market
    What is the current price of Tarsus Pharmaceuticals, Inc. - Common Stock?
    The current price of Tarsus Pharmaceuticals, Inc. - Common Stock is 68.95
    When was Tarsus Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of Tarsus Pharmaceuticals, Inc. - Common Stock was at 08/13/26 01:38 PM ET
    What is the market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of Tarsus Pharmaceuticals, Inc. - Common Stock is 2.94B
    How many shares of Tarsus Pharmaceuticals, Inc. - Common Stock are outstanding?
    Tarsus Pharmaceuticals, Inc. - Common Stock has 3B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.